Dose-escalation study for the treatment of Hodgkin's disease
- 1 March 1993
- journal article
- review article
- Published by Springer Nature in Annals of Hematology
- Vol. 66 (3), 139-140
- https://doi.org/10.1007/bf01697624
Abstract
Treatment results of Hodgkin's disease have been improved by polychemotherapy. The overall cure rate for adults is about 70%. For advanced stages of Hodgkin's disease (III B—IV), the results of treatment are less satisfactory. One approach to improving the cure rates for patients with advanced stages is the intensification of chemotherapy. The German Hodgkin Study Group (GHSG) will apply this treatment strategy by introducing a new protocol (BEACOPP) in combination with growth factor (G-CSF) support to prevent prolonged neutropenia and severe infections. In a currently initiated “run-in”-study the maximal tolerable dose of cyclophosphamide, adriamycin, and etoposide will be defined within a multicenter setting. The subsequent trial will consist of a randomized study of BEACOPP baseline vs. BEACOPP dose-intensified vs. COPP/ABVD standard, in order to evaluate the role of dose intensification for the improvement of treatment outcome.Keywords
This publication has 3 references indexed in Scilit:
- Is there an effective salvage therapy for advanced Hodgkin's disease?Annals of Oncology, 1991
- Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.Journal of Clinical Oncology, 1990
- The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture.1987